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Supplemental Methods
Study Design
A modified toxicity probability interval (mTPI) study design based on a Bayesian statistics framework and a beta/binomial hierarchical model was used to determine dose escalation/de-escalation in the dose-finding part of this study. If the toxicity rate at the selected dose level was far smaller than the target rate (pT = 0.30), the mTPI would recommend escalating the dose level; if it was close to pT, the mTPI would recommend continuing at the selected dose; if it was far greater than pT, the mTPI would recommend deescalating the dose level.
Reference: Ji Y et al. A modified toxicity probability interval method for dose-finding trials. Clin Trials. 2010; 7: 653-663.
Analysis
The safety analysis set included all enrolled patients who received at least one dose of study medication. Patients who were lost to follow-up before receiving at least 80% of 2 the planned first-cycle dose due to reasons unrelated to treatment were not evaluable for DLT. The response analysis set included all enrolled patients who had baseline assessments and at least one on-study tumor assessment. Patients who were treated and removed from the study prior to on-study tumor assessment because of disease progression were considered evaluable for efficacy and counted as treatment failures. Indeterminate response due to stable disease prior to new anticancer treatment on study day 37, thus earlier than 6 weeks. CI, confidence interval.
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